Company intelligence / Profile preview

PepTC Vaccines

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

PepTC Vaccines is developing PolyPEPI SCoV 2, a multi-peptide T‑cell–focused COVID‑19 vaccine that has shown positive preclinical immunogenicity data and is described as in preclinical development for prevention of COVID‑19.[2][3][4]

Therapeutic areas: Infectious Diseases
Modalities: VaccinePeptides
Industry: Biotech

Drug pipeline

1 asset

PolyPEPI-SCoV-2

Unknown

Beyond the preview

Go deeper on PepTC Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PepTC Vaccines.

Explore the full profile